Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research

Mol Cell Proteomics. 2003 Jun;2(6):369-77. doi: 10.1074/mcp.R300007-MCP200. Epub 2003 Jun 25.

Abstract

The application of state-of-the-art proteomics and functional genomics technologies to the study of cancer is rapidly shifting toward the analysis of clinically relevant samples derived from patients, as the ultimate aim of translational research is to bring basic discoveries closer to the bedside. Here we describe the essence of a long-term initiative undertaken by The Danish Centre for Translational Breast Cancer Research and currently underway for cancer biomarker discovery using fresh tissue biopsies and bio-fluids. The Centre is a virtual hub that brings together scientists working in various areas of basic cancer research such as cell cycle control, invasion and micro-environmental alterations, apoptosis, cell signaling, and immunology, with clinicians (oncologists, surgeons), pathologists, and epidemiologists, with the aim of understanding the molecular mechanisms underlying breast cancer progression and ultimately of improving patient survival and quality of life. The unifying concept behind our approach is the use of various experimental paradigms for the prospective analysis of clinically relevant samples obtained from the same patient, along with the systematic integration of the biological and clinical data.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Academies and Institutes*
  • Biomarkers, Tumor*
  • Biomedical Research / trends*
  • Biopsy
  • Body Fluids / chemistry
  • Breast Neoplasms / classification
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Denmark
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Gene Expression Profiling
  • Genomics*
  • Humans
  • Mammary Glands, Human / pathology
  • Pilot Projects
  • Proteomics*
  • Specimen Handling

Substances

  • Biomarkers, Tumor